INCB081776

· Incyte Corporation

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for INCB081776, covering 2025-10-09 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma [EARLY_Phase 1]